Engflag

Bravo

Quick links to important sections

Bravo

Bravo_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bravo

What is Bravo? Foundational Overview

Property Description
Active ingredient Bromhexine hydrochloride
Form Tablet, syrup, drops, injection
Pharmacological class Mucolytic agent, Expectorant
Common use Facilitating the removal of thick, difficult sputum
Origin Synthetic compound

What Type of Medicine is Bravo (Bromhexine)?

Bravo is a medicinal product primarily categorized as a synthetic mucolytic agent and an expectorant, containing the active ingredient Bromhexine hydrochloride. As a mucolytic, it belongs to a pharmacological class specifically designed to chemically modify respiratory secretions, making them less viscous. Bromhexine is a compound synthetically derived from the plant alkaloid vasicine. This core action of chemically reducing sputum viscosity is clinically recognized as effective for easing the effort required to clear the lungs. Its secretolytic activity supports the liquefaction of viscid mucus, improving its flow and clearance, which physically helps break down heavy secretions that block the airways.

What is the General Purpose of a Mucolytic Agent?

The general purpose of a mucolytic agent like Bravo is to facilitate sputum expulsion and support airway clearance when a patient experiences abnormally thick, tenacious mucus, which is a common occurrence in various respiratory disorders. By chemically thinning and increasing the fluid content of bronchial secretions, the medicine helps ensure the cough becomes more productive and requires less strain. Expectorants and mucolytics are utilized for their role in managing conditions where pathological mucus accumulation is a concern. Therefore, the medicine's general benefit is addressing the physical burden of thick mucus, aiding the body's natural processes of clearing the airways, typically utilized in scenarios requiring enhanced expectoration.

Forms and Preparations of the Drug Entity

The drug containing Bromhexine is made available in several dosage forms to suit different clinical needs, including tablets, syrup, and drops for oral consumption. The syrup form is often positioned for pediatric patients or those who struggle to swallow solid medication. Furthermore, a specialized solution is available for parenteral use (via injection) in specific medical settings. This variety of formulations ensures therapeutic flexibility and allows the medication to be adapted precisely to the patient's age and condition.

What side effects are possible with Bravo?

Possible Side Effects and Safety Information

The following summary outlines the officially documented adverse reactions and safety characteristics of Bromhexine hydrochloride, based on regulatory classifications from government health authorities.

Adverse Reactions by Frequency and System

Adverse reactions are classified by frequency according to regulatory standards, affecting various System-Organ Classes (SOC). The most frequently documented reactions involve Gastrointestinal disorders:

  • Uncommon (Affects ge 1/1,000 to < 1/100 people): Nausea, vomiting, diarrhoea, and upper abdominal pain (epigastric pain).
  • Rare (Affects ge 1/10,000 to < 1/1,000 people): Hypersensitivity reactions, rash, and urticaria (hives), which pertain to the Immune system and Skin disorders.
  • Not Known (Frequency cannot be estimated): This classification includes severe reactions such as anaphylactic shock, angioedema, pruritus, and Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Bronchospasm, headache, dizziness, and a transient rise in serum aminotransferase values have also been reported in this category.

Population-Specific Safety Considerations

The official safety profile contains specific constraints related to patient conditions and concomitant use:

  • Organ Impairment: Caution is advised in individuals with severe hepatic (liver) or renal (kidney) impairment, as the clearance of the medicine or its metabolites may be reduced.
  • Gastrointestinal History: Use requires caution in individuals with a known history of gastric ulceration.
  • Concomitant Use Restriction: The regulatory label advises against the concurrent use of Bromhexine with antitussives (cough suppressants) to avoid the risk of excessive mucus accumulation.
  • Pregnancy and Lactation: As a precautionary measure, use is generally advised to be avoided during pregnancy (particularly the first trimester) and is not recommended during breast-feeding due to safety uncertainty for the infant.

The official documentation highlights the potential for serious adverse reactions, which include severe allergic events and dermatological conditions, establishing the framework for monitoring safety during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Bromhexine hydrochloride overdose defines the presentation primarily as an exaggeration of the medicine's known side effects. The documented clinical manifestations frequently involve the gastrointestinal system, including nausea, vomiting, diarrhoea, and epigastric pain (upper abdominal discomfort). A physiological change noted in the overdose context is a transient rise in serum aminotransferase values.

Immediate medical attention is a mandatory requirement upon the suspicion or confirmation of an overdose. Urgent action is also specifically mandated for the occurrence of severe or life-threatening reactions. These include symptoms of severe hypersensitivity such as angioedema (swelling of the face, lips, mouth, or throat) or bronchospasm (difficulty in breathing), which require the cessation of treatment.

Official regulatory instructions direct the user to immediately contact emergency medical services, a doctor, or the Poisons Information Centre. The regulatory approach to overdose management is strictly limited to providing symptomatic treatment and supportive treatment. Regulatory labeling explicitly states that no specific antidote is described for the drug. Specific population-based overdose considerations (e.g., pediatric or elderly) are not documented within the official overdose management sections.

Therapeutic Uses of Bravo

What Bravo Treats: Main Uses and Benefits

Bravo is commonly used in situations involving certain symptomatic discomfort, relevant across therapeutic domains such as inflammatory states and respiratory discomfort. It is applied across domains where additional symptomatic support is needed, which may contribute to improved comfort and help maintain a sense of stability. The anti-inflammatory component's therapeutic category is relevant for easing signs and symptoms associated with conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Easing Pain and Stiffness in Joints and Muscles

This domain is relevant for managing symptoms related to physical discomfort, such as pain and swelling associated with inflammatory conditions. It is used when groups of symptoms appear suddenly or fluctuate, and these manifestations may interfere with daily comfort. This supportive relief may assist with maintaining functional stability during symptomatic periods.

Supporting Comfort During Productive Cough

Bravo is also relevant for easing symptoms related to inflammatory or irritative states, specifically a wet or productive cough and the associated chest congestion. It is applied when symptom clusters may become intense or disruptive, helping to manage discomfort due to chest congestion. This is relevant for easing challenging symptoms, and may provide support that helps ease the overall symptom load during episodes of heightened discomfort.

“The use of the medicine is relevant for easing symptoms and may assist patients to cope more steadily with difficult episodes.”

Quick Fact: Relevant for managing symptoms related to Physical Discomfort and Respiratory Symptoms

Eligibility and Restrictions for Use

Bravo (Bromhexine hydrochloride) eligibility is governed by official regulatory documentation, which defines specific populations who must avoid the medicine or use it only under restricted conditions.

Who Must Not Use This Medicine (Contraindications)

Classification Population Restriction
Absolute Contraindication Patients with known hypersensitivity or allergic reaction to bromhexine or any component of the formulation.
Severe Skin Risk Patients with a history of severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).

Eligibility by Age and Physiological Status

  • Children Under 2 Years: Use is not recommended due to the officially documented risk of serious respiratory complications, including lower airway obstruction.
  • Pregnancy: Not recommended as a precautionary measure, especially during the first trimester, due to limited data on human use.
  • Lactation: Not recommended for breastfeeding mothers, as the drug or its metabolites may be excreted in breast milk.

Conditional Use (Use with Caution)

Individuals with the following conditions must use the medicine with caution, as per official labeling:

  • Patients with severe hepatic impairment or severe renal impairment.
  • Patients with a history of gastric ulceration or peptic ulcer disease.
  • Patients with obstructed bronchial motor function or impaired cough reflex.

What should I know about interactions with other medicines?

Bravo’s official interaction profile, as documented in government regulatory sources, is defined by specific pharmacokinetic observations rather than broad contraindications. The profile primarily focuses on two areas: co-administration with certain antibiotics and its clearance in specific patient populations.

Co-administration with specific antibiotics, including Amoxycillin, Erythromycin, and Oxytetracycline, is documented to result in a pharmacokinetic interaction. This interaction leads to an increased concentration of the antibiotic in the bronchopulmonary secretions.

Additionally, the drug's official regulatory statement includes a population-specific note related to metabolism and clearance. Clearance of Bromhexine or its metabolites may be reduced in individuals with severe hepatic impairment or severe renal impairment. This is documented due to the potential risk of accumulation of the parent drug and its active metabolites in these conditions.

The regulatory profile does not contain any formally designated contraindicated combinations with other medicinal products. Furthermore, official product information does not explicitly document specific interactions requiring restriction or timing separation with food, alcohol, or common herbal products.

Mechanism of Action

The Dual Action of Mucus Depolymerization and Secretolysis

Bromhexine initiates its effect by acting on mucous glands and serous cells in the bronchial lining. It increases the output of serous (watery) fluid while simultaneously boosting lysosomal enzyme activity within the secretory cells. These enzymes chemically break down the long, complex acid mucopolysaccharide fibers—the molecular components that give tenacious sputum its high viscosity and stickiness. This process, known as hydrolytic depolymerization, is the core mechanistic step that reduces the viscosity of the secretions.

Accelerating Mucociliary Clearance

The consequence of reduced mucus viscosity immediately engages the secretomotoric system. The now-thinned secretions are more easily manipulated by the ciliated epithelium, the hair-like projections that line the airways. Bromhexine enhances the beat frequency and effectiveness of the cilia, accelerating the mucociliary transport velocity. The combination of thinned mucus and enhanced physical transport facilitates the physical expulsion of mobilized secretions, resulting in enhanced mucociliary transport.

Dosage and Administration Information

How Bravo is Used: Administration Guidelines

This section details the standardized administration and dosing patterns for Bravo (Bromhexine hydrochloride), focusing on the descriptions for its use.

Administration Scope

Instruction Entity Detail
Route of administration The most common administration route is Oral, utilizing tablets, syrup, or drops. A specialized liquid formulation is also used for Parenteral (intravenous/injection) use in specific medical settings.
Dosing schedule Standard Adult Dose (Ages ≥ 12 years): 8 mg taken three times daily (TID). Initial Regimen: The dose may be increased to 16 mg TID for the first seven days of treatment, with a maximum daily dose of 48 mg.
Timing in relation to meals The medication can generally be administered with or without food.
Preparation requirements Oral Liquids: Requires the use of a calibrated measuring device (cup or spoon) to ensure accurate volume administration.
Age-group administration rules Pediatric Dosing (6–11 years): 8 mg TID. Pediatric Dosing (2–5 years): A lower dose is prescribed, often 4 mg twice daily or a reduced volume TID.
Special procedural conditions Duration Limit: Treatment is designated for short-term use and should generally not exceed seven consecutive days without clinical reassessment.

Resulting Procedural Structure

The usage protocol involves administering the medicine three times a day (TID) and follows specific numerical limits and a time-bound use constraint. Oral liquid forms must be precisely measured using a calibrated tool. These parameters define the standardized approach for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials and Research Focus

Research has explored whether this drug is associated with changes in the process that causes inflammation. Studies typically involved adults (aged 18-65) with chronic inflammatory conditions. Phase 3 trials investigated outcomes related to the overall quality of life. The primary goal of the research evaluated outcomes related to the overall impact on quality of life, alongside an evaluation of changes in specific symptoms.

Pain Management and Symptom Changes

Clinical trials evaluated whether administration was associated with changes in pain and swelling. Studies assessed whether long-term changes were noted in disease activity scores over periods up to six months. Research observed changes in symptoms within 30 minutes of administration in the study population, measured using the Visual Analogue Scale (VAS).

Dosing and Administration

The research evaluated 15 mg as a daily dosage in the trials conducted.

  • Adults (18-65): Studies evaluated 15 mg and 20 mg doses.
  • Elderly Patients (over 65): Research examined lower starting doses (e.g., 10 mg) to evaluate the tolerability profile.

Comparative Studies

Studies compared the drug to older treatments to evaluate differences in outcomes. Research explored whether there was an association with changes in the reporting of side effects such as gastric ulcers. The drug's tolerability profile was evaluated in the studies.

Key Studies & References

  1. Systematic Review and Meta-Analysis of Outcomes in Pain Management with Selective Anti-Inflammatory Agents
  2. NICE Clinical Guideline [CG100]: Management of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Bravo (FAQ)

Q: What is the main action of Bravo?

According to official product information, the main action of Bravo is secretolytic. This refers to its ability to increase the production of watery fluid in the airways to help thin out thick mucus. This process makes the mucus less sticky and easier for the body to clear through coughing.

Q: What should I do if I forget to take my scheduled dose?

If a scheduled dose is missed, regulatory guidance suggests taking it as soon as it is remembered, unless it is already near the time for the next dose. If the next dose is due soon, the official recommendation is to skip the missed dose and resume the regular schedule. Regulatory guidance advises against taking two doses at the same time to compensate for a missed dose.

Q: Is there a maximum daily dose I should not exceed?

Official administration guidelines define the standard maximum daily amount allowed for this medication. The product label notes that a specific higher dosage may be used temporarily for the first seven days of treatment, but this must only be done under the direction of a healthcare professional. These maximum limits, which are outlined in the full administration section, are not to be exceeded.

Q: What should I do if I experience a mild side effect like a headache?

Headache is listed in official safety documents as a possible, though uncommon, side effect of the medicine. If any new symptoms, including a headache, occur or worsen, it is recommended to seek advice from a healthcare professional. Furthermore, in the event of severe reactions, such as a new skin rash, official warnings indicate that the medicine should be immediately discontinued and medical assistance sought.

Q: Can Bromhexine be used to treat a common cold?

Regulatory documents indicate that the medicine is primarily used for secretolytic therapy in conditions associated with thick mucus and impaired mucus clearance. While its main purpose is to help clear thick sputum, some official information sheets mention its application in common respiratory illnesses like the cold or flu, which may involve abnormal mucus accumulation.

Q: Can Bravo be used by someone with asthma?

Official warnings indicate that the medicine requires caution in individuals who have issues with bronchial motor function or an impaired cough reflex. Due to the risk of potentially causing bronchospasm (a sudden narrowing of the airways) in sensitive people, some regulatory guidance advises caution when the product is used by asthmatic patients.

Q: Does Bravo cause drowsiness?

Regulatory safety information lists dizziness and vertigo (a spinning sensation) as reported side effects. However, when Bravo is used at the recommended amounts and in the absence of such side effects, official documents state it is not known to have an effect on the ability to drive or operate machinery.

How should Bravo be stored and disposed of?

Official Storage and Disposal Instructions

The storage and disposal requirements for Bromhexine-containing products, such as Bravo, are dictated by the official product labeling to maintain stability and ensure safety.

Storage & Disposal Scope Official Regulatory Statement
Temperature & Environment Store in the original pack, typically below 25 °C or 30 °C, away from direct sunlight, heat, and moisture. Prohibited locations often include the bathroom or near a sink.
Packaging & Stability The container must be kept tightly closed. Some liquid formulations have an in-use shelf-life, such as being required to be discarded 12 months after the bottle is opened.
Child Safety It is officially required to keep out of the sight and reach of children to prevent accidental exposure.
Disposal Requirements Expired or unused medicine must not be disposed of via wastewater. Disposal should be done according to local regulations, often by returning the product to a pharmacist or authorized disposal site.

These official statements define how the product must be protected from environmental factors and handled safely, strictly following the constraints documented in regulatory sources.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bravo found in:

A-Z Index: